Marshall Wace, LLP Cellectis S.A. Transaction History

Marshall Wace, LLP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$2.29 - $4.08 $13,046 - $23,243	-5,697 Reduced 4.98%	108,744 $249,000
Q2 2022 Aug 15, 2022	SELL	$2.39 - $4.93 $75,899 - $156,562	-31,757 Reduced 21.72%	114,441 $324,000
Q1 2022 May 16, 2022	BUY	$3.45 - $8.77 $485,463 - $1.23 Million	140,714 Added 2565.9%	146,198 $663,000
Q4 2021 Feb 14, 2022	BUY	$8.01 - $12.84 $43,926 - $70,414	5,484 New	5,484 $44,000
Q3 2020 Nov 16, 2020	SELL	$15.7 - $20.84 $604,010 - $801,756	-38,472 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$8.21 - $21.02 $315,855 - $808,681	38,472 New	38,472 $685,000
Q4 2019 Feb 14, 2020	SELL	$9.73 - $19.31 $158,044 - $313,652	-16,243 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$10.15 - $16.89 $337,396 - $561,440	-33,241 Reduced 67.18%	16,243 $169,000
Q2 2019 Aug 14, 2019	BUY	$14.6 - $20.6 $722,466 - $1.02 Million	49,484 New	49,484 $772,000

11.2M

2.8K

17.9K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $82.8M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.